Tetraphase Pharmaceuticals, Inc.
TTPH
TTPH was delisted on the 28th of July, 2020.
23 hedge funds and large institutions have $1.94M invested in Tetraphase Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 7 closing their positions.
12% less funds holding
Funds holding: 26 → 23 (-3)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
27% less capital invested
Capital invested by funds: $2.67M → $1.94M (-$733K)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$480K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$199K |
| 3 |
Renaissance Technologies
New York
|
+$199K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$214K |
| 2 |
Two Sigma Investments
New York
|
-$112K |
| 3 |
JP Morgan Chase
New York
|
-$32K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$22K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$19.7K |
TTPH Hedge Fund Activity: Q4 2019 in Review
23 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q4 2019, worth a combined $1.94M — down 27% from $2.67M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TTPH and 4 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $480K. The largest seller was Vanguard Group, cutting an estimated $214K.
- 23 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q4 2019, down from 26 in Q3 2019.
- Funds reported $1.94M of Tetraphase Pharmaceuticals, Inc. stock for Q4 2019, down 27% quarter-over-quarter.
- 4 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q4 2019 and 7 closed out, a net change of -3 holders.
- The largest Tetraphase Pharmaceuticals, Inc. buyer in Q4 2019 was Armistice Capital, an estimated $480K added.
- The largest Tetraphase Pharmaceuticals, Inc. seller in Q4 2019 was Vanguard Group, an estimated $214K sold.
Based on aggregated 13F filings for Q4 2019.